Skip to Main Content

Paper Details

First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01.
J Clin Oncol
8
2023
Dato, Datopotamab, Deruxtecan, Human, Interstitial lung disease, NSCLC, Non-Small-Cell Lung Cancer, TROP2, Trophoblast Cell-Surface Antigen 2, advanced NSCLC, advanced non-small-cell lung cancer, alopecia, datopotamab, deruxtecan, human, locally advanced/metastatic NSCLC, nausea, patients, solid tumors, stomatitis, trophoblast cell-surface antigen 2
Author NameAffiliation
Edward B GaronDavid Geffen School of Medicine at university of california los angeles
Edward B GaronDavid Geffen School of Medicine at university of california los angeles
Funda Meric-BernstamThe University of Texas MD Anderson Cancer Center
Aaron LisbergDavid Geffen School of Medicine at university of california los angeles
Aaron LisbergDavid Geffen School of Medicine at university of california los angeles
  • 1 - 5

Datasets

Release 1.2